Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Suspended 1Active not recruiting 1

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2Thoracic 1Plasma cell 1Other hematologic neoplasm 1Lymphoid 1Head & Neck 1Gynecologic 1Gastrointestinal 1Dermatologic 1CNS 1Breast 1

Conditions

Multiple Myeloma 14Leukemia, Myeloid, Acute 13Lymphoma 12Neoplasm Metastasis 11Pancreatic Neoplasms 9Prostatic Neoplasms 8Myelodysplastic Syndromes 8Burkitt Lymphoma 8Breast Neoplasms 8Glioma 7Colorectal Neoplasms 7Sarcoma 6Leukemia, Lymphocytic, Chronic, B-Cell 6Triple Negative Breast Neoplasms 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Neuroblastoma 5Lymphoma, T-Cell 5Lymphoma, Non-Hodgkin 5Central Nervous System Neoplasms 5Carcinoma, Renal Cell 5Wilms Tumor 4Squamous Cell Carcinoma of Head and Neck 4Rhabdoid Tumor 4Ovarian Neoplasms 4Oropharyngeal Neoplasms 4Neuroectodermal Tumors, Primitive, Peripheral 4Medulloblastoma 4Lung Neoplasms 4Histiocytosis, Langerhans-Cell 4Hepatoblastoma 4

Interventions

Gemcitabine 11Magnetic Resonance Spectroscopy 10Specimen Handling 8Cisplatin 7pembrolizumab 6Radiation 5Mitomycin 4Fluorouracil 4Cystoscopy 4enfortumab vedotin 3durvalumab 3dehydroftorafur 3avelumab 3Transurethral Resection of Bladder 3Radiotherapy 3Platinum 3Nivolumab 3Mitozytrex 3Cystectomy 31,2-diaminocyclohexaneplatinum II citrate 3ulixertinib 2tremelimumab 2erdafitinib 2atezolizumab 2Paclitaxel 2Immunoglobulin G 2Docetaxel 2Disulfides 2Carboplatin 2Biopsy 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Urinary Bladder Neoplasms × Biopsy × 30 days × Clear all
NCT03375307 2026-06-05

Testing Olaparib in Patients With Advanced or Metastatic (Cancer That Has Spread) Bladder Cancer and Other Genitourinary Tumors With DNA-Repair Genetic Changes

National Cancer Institute (NCI)

Phase 2 Suspended
60 enrolled
Genitourinary

Urinary Bladder Neoplasms

NCT02465060 2026-06-03

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

National Cancer Institute (NCI)

Phase 2 Active not recruiting
6,452 enrolled 1 FDA
BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidOther hematologic neoplasmPlasma cellThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Glioma, Carcinoma, Hepatocellular, Lung Neoplasms, Lymphoma, Melanoma, Multiple Myeloma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms, Thyroid Neoplasms, Uterine Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡